Overview

TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Status:
Not yet recruiting

Trial end date:
2023-03-31

Target enrollment:

Participant gender:

Summary

This is a randomized pilot trial of weekly paclitaxel and bevacizumab with or without zoledronic acid in women with platinum-resistant epithelial ovarian cancer with 1-2 prior regimens for recurrence.

Phase:

Early Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

Gateway for Cancer Research
National Cancer Institute (NCI)

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel